Rafael V Davalos

Blacksburg, VA, United States of America

Rafael V Davalos

This inventor holds 66 USPTO granted patents and 25 published patent applications, plus 1 CIPO patent and 4 EPO patents, primarily in Electroporation Technology (CPC class A61B). Top assignees: Virginia Tech Intellectual Properties Inc., Angiodynamics, Inc., University of California. Active years: 2008-2026.

USPTO Granted Patents = 66 

% Patents Active = 93.9


 

Average Co-Inventor Count = 3.0

ph-index = 33

Forward Citations = 3,159(Granted Patents)

Forward Citations (Not Self Cited) = 1,578(Dec 10, 2025)


Inventors with similar research interests:


Location History:

  • Oakland, CA (US) (2008 - 2021)
  • Blacksburg, VA (US) (2010 - 2024)

Company Filing History:


Years Active: 2008-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Electroporation
Tissue Ablation
Blood-Brain Barrier
Immunotherapy
Non-Thermal Ablation
Cell Manipulation
Electrical Pulses
Tissue Heating
Real-Time Monitoring
Dielectrophoresis
Treatment Planning
66 patents (USPTO):Explore Patents

Title: Inventor Rafael V Davalos

Introduction: Rafael V Davalos is a renowned inventor based in Blacksburg, VA (US) known for his groundbreaking contributions to the field of innovation and technology.

Latest Patents: Rafael V Davalos holds several patents in the areas of medical devices and biotechnology, showcasing his expertise and creativity in developing cutting-edge solutions.

Career Highlights: With a distinguished career spanning over two decades, Rafael V Davalos has worked tirelessly to push the boundaries of science and technology, earning recognition for his impactful inventions.

Collaborations: Throughout his career, Rafael V Davalos has collaborated with leading research institutions, universities, and companies to further his innovative projects and bring his ideas to life.

Conclusion: In conclusion, Rafael V Davalos stands as a visionary inventor whose work continues to inspire and shape the future of technology and innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…